We use cookies necessary to giving you a better online experience. By using our website you consent to all cookies in accordance with our Privacy Policy.
Yes, I accept
Menu
Search Opener
Vienna, Austria

ESTRO 2025

Session

Urology - prostate, bladder, penis
Digital Poster
Brachytherapy
Imaging and AI supported transformation to better practice – MR fusion target boost low dose rate prostate brachytherapy
Diane Whitney, United Kingdom
E25-167
Spanish Salvage Prostate Brachytherapy (RESPRO STUDY) in the NGI era.
Patricia Willisch Santamaria, Spain
E25-2534
HDR brachytherapy as monotherapy in the treatment of high-risk prostate cancer
Oxana Komina, Austria
E25-2579
Single-insertion multi-fraction HDR brachytherapy for prostate cancer: feasibility and short-term outcomes in a lower-middle-income country setting
Carl Jay Jainar, Philippines
E25-3125
High Dose Rate Brachytherapy Boost in intermediate and high risk localised prostate cancer. A retrospective study on toxicity and clinical outcomes.
mahbuba choudhury, United Kingdom
E25-3495
Brachytherapy as monotherapy in prostate cancer. Long term outcomes and predictive value of nadir PSA. The role of artificial intelligence.
SILVIA RODRIGUEZ VILLALBA, Spain
E25-3618
LONG TERM OUTCOME AFTER LOW-DOSE-RATE BRACHYTHERAPY FOR PROSTATE CANCER IN ONE OF THE LARGEST PATIENT COHORTS WORLDWIDE: TRENTO HOSPITAL EXPERIENCE
Laura Bandera, Italy
E25-4022
Multimodal therapy for synchronous rectal and prostate cancer using EBRT and HDR brachytherapy as a boost.
Michał Kurzyński, Poland
E25-4408
The association between dose and location of the dominant intraprostatic lesion with outcomes in patients treated with LDR prostate brachytherapy
Suneil Jain, United Kingdom
E25-4594
PSMA-PET staged organ-confined Prostate cancer managed by combined hypofractionated radiotherapy: primary endpoint analysis of a prospective study
Iosif Strouthos, Cyprus
E25-378
Planning feasibility study for HDR-brachytherapy to treat muscle invasive bladder cancer
Liam Mannion, United Kingdom
E25-537
Are low PSA nadir and delayed time to PSA nadir the goals to reach in patients with prostate cancer treated with LDR-BT?
Patricia Willisch Santamaria, Spain
E25-605
Physical and biological (EQD 2 ) dose comparisons in various prostate radiation regimens
Joerg Zimmermann, Germany
E25-857
Long-term outcomes of external beam radiation therapy with high-dose-rate brachytherapy boost in very high-risk prostate cancer
Ana Laura Rivero Pérez, Spain
E25-1144
Long-Term Outcomes of High-Dose-Rate Brachytherapy Combined with Hypofractionated External Beam Radiotherapy for High-Risk Prostate Cancer
Kenta Ohmatsu, Japan
E25-1710
Salvage High-Dose-Rate Brachytherapy for Local Recurrent Prostate Cancer: survival and toxicity of a necessary therapeutic option.
Lucia Biscari, Spain
E25-2478